Status:
UNKNOWN
Rare Variation and Remote Gene Regulation of Osteoporosis Related Phenotypes in Han Chinesse
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborating Sponsors:
Westlake University
Conditions:
Senile Osteoporosis With Current Pathological Fracture Lower Leg (Diagnosis)
Eligibility:
All Genders
50-100 years
Brief Summary
Bone density is recognized as the most important factor to measure osteoporosis, and the prevalence of osteoporosis increases with age. Risk factors for osteoporosis include age, weight, exercise, die...
Detailed Description
From past linkage analysis and candidate gene association studies to genome-wide association studies and second-generation sequencing technologies, researchers have found hundreds of genes and SNPs as...
Eligibility Criteria
Inclusion
- From July 2018 to July 2021, patients admitted to the outpatient or inpatient clinic were diagnosed as primary osteoporosis fracture;
- Aged between 50 and 100;
- This fracture was not treated with any anti-osteoporosis drugs before
- Subjects will participate in the study voluntarily and have signed the informed consent
- Patients with clear mind and independent behavioral ability
Exclusion
- Patients with malignant tumors are associated with bone metastases, such as lung cancer, prostate cancer, thyroid cancer, etc
- Hyperparathyroidism, Cushing syndrome, hypogonadism, hyperthyroidism, pituitary prolactinoma, diabetes
- Systemic lupus erythematosus, rheumatoid arthritis, sjogren's syndrome, dermatomyositis, mixed connective tissue disease, etc.;
- Renal osteodystrophy caused by various chronic kidney diseases;
- Gastrointestinal diseases and nutritional diseases: malabsorption syndrome, subtotal gastrectomy, chronic pancreatic diseases, chronic liver diseases, protein-calorie malnutrition, long-term intravenous nutrition support treatment, etc.;
- Leukemia, lymphoma, multiple myeloma, hyperthermia and myelodysplastic syndrome;
- Hemiplegia, paraplegia, motor dysfunction, muscular dystrophy, catalepsy and myotonic syndrome caused by various reasons;
- Glucocorticoids, immunosuppressants, heparin, anticonvulsants, anticancer drugs, aluminum-containing antacids, thyroid hormones, gnrh-a or dialysate, etc.
- Unwilling to accept dietary management or unable to sign the informed consent
Key Trial Info
Start Date :
April 29 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT04129671
Start Date
April 29 2019
End Date
December 31 2021
Last Update
October 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejing Province, China, 310009